This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BD (BDX) to Boost Pre-Fillable Syringe-Manufacturing Capacity
by Zacks Equity Research
BD (BDX) is set to improve its pre-fillable syringe-manufacturing ability with its expansion and upgrade plans.
AMN Healthcare (AMN) Boosts Service Portfolio With New Offering
by Zacks Equity Research
AMN Healthcare's (AMN) new pledge to provide support minority-owned businesses, thereby helping them to thrive.
Why You Should Add Merit Medical (MMSI) to Your Portfolio
by Zacks Equity Research
Investor confidence is high on Merit Medical (MMSI) stock, courtesy of its solid prospects.
Medtronic (MDT) Shows Strong Sales Recovery Amid COVID-19 Crisis
by Zacks Equity Research
Based on the ongoing strong recovery in sales, Medtronic (MDT) expects fiscal third-quarter MITG growth to be in the low single digits.
Baxter (BAX) Gets FDA Nod for Homechoice Claria APD System
by Zacks Equity Research
Baxter's (BAX) Homechoice Claria combines a simple user interface with the benefits of Sharesource.
CAH vs. ALGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
CAH vs. ALGN: Which Stock Is the Better Value Option?
Here's Why You Should Hold on to CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investor confidence is high on CONMED (CNMD) stock, thanks to solid prospects.
Top Ranked Momentum Stocks to Buy for November 25th
by Nitish Marwah
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 25th.
Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (CAH) Outperforming Other Medical Stocks This Year?
Here's Why You Should Invest in Cooper Companies (COO) Stock
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from solid CVI and CSI product portfolios.
Ecolab (ECL) Gets EPA Nod for Biofilm Disinfectant Virasept
by Zacks Equity Research
Ecolab's (ECL) Virasept has been developed to combat bacterial growth in hospitals.
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on DaVita (DVA) stock, thanks to solid prospects.
Here's Why You Should Avoid Betting on Integer Holdings (ITGR)
by Zacks Equity Research
Stiff competition in the MedTech space and weak segmental and operational third-quarter 2020 performance weighs on Integer Holdings (ITGR).
Top Ranked Momentum Stocks to Buy for November 20th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 20th.
NextGen (NXGN) Strengthens Portfolio of NextGen Solutions
by Zacks Equity Research
NextGen (NXGN) continues to boost its robust portfolio of NextGen solutions with the latest adoption of NextGen Enterprise by OSMC.
Rising P/E: An Ignored Trick to Pick 5 Winning Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Veeva Systems (VEEV) Boosts Portfolio of Cloud-Based Offerings
by Zacks Equity Research
Veeva Systems (VEEV) continues to boost its cloud-based offerings profile with the adoption of Vault PromoMats by Bristol Myers.
Here's Why You Should Invest in Cardinal Health (CAH) Stock
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and strategic buyouts.
LHC Group (LHCG) Forays into Oklahoma With New Hospice Buyout
by Zacks Equity Research
LHC Group (LHCG) buys Grace Hospice of Oklahoma to expand its hospice service to Tulsa and throughout the nation.
Here's Why You Should Retain Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.
PerkinElmer's Non-Invasive Saliva-Based Testing Gets CE Mark
by Zacks Equity Research
PerkinElmer's (PKI) new saliva-based collection and asymptomatic test solution receives CE-IVD mark.
Why Cardinal Health (CAH) is Such a Great Value Stock Pick Right Now
by Zacks Equity Research
Cardinal Health (CAH) seems to be a good value pick, as it has decent revenue metrics to back up its earnings, and is seeing solid earnings estimate revisions as well.
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
CAH vs. ALGN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CAH vs. ALGN: Which Stock Is the Better Value Option?
Has Cardinal Health (CAH) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (CAH) Outperforming Other Medical Stocks This Year?